Key result
Angiotensin II shows greater mesenteric vasoconstrictor potency and duration than angiotensin III.
Why the study?
Differential changes in mesenteric blood flow may contribute to the greater vasopressor potency of angiotensin II compared to angiotensin III.
Does angiotensin II have a greater vasoconstrictor effect than angiotensin III in the mesenteric circulation of anesthetized dogs?
Does angiotensin II have a greater vasoconstrictor effect than angiotensin III in the mesenteric circulation of anesthetized dogs?
Angiotensin II is a more potent mesenteric vasoconstrictor than angiotensin III, contributing to its greater effect on arterial pressure, independent of prostaglandins.
Answers are grounded in this paper and cite their sources.
Angiotensin II potency in canine mesentery warrants no clinical extrapolation; leaves open peptide-specific effects in human splanchnic regulation.
Angiotensin II is more potent as a vasopressor than angiotensin III when given intravenously.We tested the hypothesis that differential changes in mesenteric blood flow contribute to this difference in potency.The effects of angiotensin II and angiotensin III on mesenteric blood flow were compared in 31 dogs anesthetized with pentobarbital.These agonists were administered either as bolus injections (10-160 pmol) or as constant infusions (30 pmol/min per kg) directly into the vasculature supplied by the superior mesenteric artery.Approximately equipressor doses of angiotensin II (40 pmol/min per kg) and angiotensin III (80 pmol/min per kg) also were given intravenously.On the basis of duration and graphic integration of the response in mesenteric blood flow, but not on the basis of absolute change in amplitude, angiotensin II was consistently more potent than angiotensin III as a mesenteric vasoconstrictor.The intra-arterial and intravenous constant infusion doses were repeated after the administration of meclofenamate (4 mg/kg, iv).Meclofenamate did not alter any of the responses to angiotensin II or angiotensin III.We conclude that the differential constrictor properties of these compounds in the mesenteric vasculature contribute to the greater potency of intravenously administered angiotensin II on arterial pressure.The results provide no evidence for an interaction between prostaglandins and the vasoconstrictor properties of angiotensin II or III in the intact mesenteric vasculature of the anesthetized dog.
No takes yet. Share an insight, caveat, or question.
Britton et al. (1980) studied this question. Angiotensin II vs. Angiotensin III was evaluated on Changes in mesenteric blood flow. Angiotensin II was consistently more potent than angiotensin III as a mesenteric vasoconstrictor based on duration and integrated response in mesenteric blood flow, unaffected by meclofenamate.
Synapse has enriched 10 related papers. Consider them for comparative context: